Evidence map›Paper›PMID 28233100›Full record

ArticlePediatric nephrology (Berlin, Germany)2017

Mesangial C4d deposition may predict progression of kidney disease in pediatric patients with IgA nephropathy.

Rafaela Cabral Gonçalves Fabiano, Stanley de Almeida Araújo, Eduardo Alves Bambirra, Eduardo Araújo Oliveira, Ana Cristina Simões E Silva, Sérgio Veloso Brant Pinheiro

Erratum issuedAbstract readComparative Study
PubMed Publisher
In one paragraph

Article in Pediatric nephrology (Berlin, Germany), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 33 citations in OpenAlex.

  1. Review
  2. Review
  3. New prognostic markers for IgA nephropathy in children.Pediatric nephrology (Berlin, Germany) · 2026
    Review
  4. Article
  5. Article
  6. Article
  7. Biomarkers in pediatric glomerulonephritis and nephrotic syndrome.Pediatric nephrology (Berlin, Germany) · 2021
    Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Complement-mediated microangiopathy in IgA nephropathy and IgA vasculitis with nephritis.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2019
    Article
  14. Review
  15. Article
  16. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Rafaela Cabral Gonçalves FabianoDivision of Clinical Nephrology, Clinics Hospital, Federal University of Minas Gerais, Belo Horizonte, Minas Gerais, Brazil.
Stanley de Almeida AraújoDivision of Renal Pathology, Clinics Hospital, Federal University of Minas Gerais, Belo Horizonte, Minas Gerais, Brazil.
Eduardo Alves BambirraDivision of Renal Pathology, Clinics Hospital, Federal University of Minas Gerais, Belo Horizonte, Minas Gerais, Brazil.
Eduardo Araújo OliveiraDepartment of Pediatrics, Pediatric Nephrology Unit, Faculty of Medicine, Federal University of Minas Gerais, Belo Horizonte, Minas Gerais, Brazil.
Ana Cristina Simões E SilvaDepartment of Pediatrics, Pediatric Nephrology Unit, Faculty of Medicine, Federal University of Minas Gerais, Belo Horizonte, Minas Gerais, Brazil.
Sérgio Veloso Brant PinheiroDepartment of Pediatrics, Pediatric Nephrology Unit, Faculty of Medicine, Federal University of Minas Gerais, Belo Horizonte, Minas Gerais, Brazil. svbpinheiro@gmail.com.
Universidade Federal de Minas Gerais · BRHospital das Clínicas da Universidade Federal de Minas Gerais · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundData on the risk factors for chronic kidney disease in children with immunoglobulin A nephropathy (IgAN) are scarce. This study was aimed at investigating whether glomerular C4d immunostaining is a prognostic marker in pediatric IgAN.

methodsIn this retrospective cohort study, 47 patients with IgAN biopsied from 1982 to 2010 were evaluated. Immunohistochemistry for C4d was performed in all cases. For analysis, patients were grouped according to positivity or not for C4d in the mesangial area. Primary outcome was a decline in baseline estimated glomerular filtration rate (eGFR) by 50% or more.

resultsMedian follow-up was 8.3 years. Median renal survival was 13.7 years and the probability of a 50% decline in eGFR was 13% over 10 years. Nine children exhibited the primary outcome and 4 developed end-stage renal disease (ESRD). Compared with C4d-negative patients (n = 37), C4d-positive patients (n = 10) presented higher baseline proteinuria (1.66 ± 0.68 vs 0.47 ± 0.19 g/day/1.73 m2, p < 0.001), a progressive decline in eGFR (−10.04 ± 19.38 vs 1.70 ± 18.51 ml/min/1.73 m2/year; p = 0.045), and more frequently achieved the primary outcome (50.0 vs 10.8%, p = 0.013), and ESRD (30.0 vs 2.7%, p = 0.026). No difference was observed in Oxford classification variables. Baseline proteinuria, endocapillary hypercellularity and mesangial C4d deposition were associated with primary outcome in univariate analysis. Proteinuria and mesangial C4d deposition at baseline independently predicted the decline in eGFR. Renal survival was significantly reduced in C4d-positive patients (8.6 vs 15.1 years in C4d-negative patients, p < 0.001).

conclusionsIn this exclusively pediatric cohort, positivity for C4d in the mesangial area was an independent predictor of renal function deterioration in IgAN.

Indexed as

BiomarkersBiopsyChildComplement C4bDisease ProgressionFemaleFollow-Up StudiesGlomerular Filtration RateGlomerular MesangiumGlomerulonephritis, IGAHumansImmunohistochemistryKidney Failure, ChronicMalePeptide FragmentsPrognosisBiomarkersComplement C4bcomplement C4dPeptide FragmentsC4d stainingChildrenChronic kidney diseaseGlomerulonephritisIgA nephropathyProteinuriaRenal function

Identifiers

PMID28233100
OpenAlexW2589663277

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.